OncoAlert (@oncoalert) 's Twitter Profile
OncoAlert

@oncoalert

🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨

ID: 1109128247789395968

linkhttp://www.OncoAlert360.com calendar_today22-03-2019 16:22:35

103,103K Tweet

38,38K Takipçi

157 Takip Edilen

OncoAlert (@oncoalert) 's Twitter Profile Photo
OncoAlert
@oncoalert

3 months ago

Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study buff.ly/JIAtTJe Amivantamab, a bispecific EGFR-MET antibody with immune cell-engaging properties, demonstrated

Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study buff.ly/JIAtTJe Amivantamab, a bispecific EGFR-MET antibody with immune cell-engaging properties, demonstrated